Search

Your search keyword '"Dirk Lebrecht"' showing total 2 results
Start Over Author "Dirk Lebrecht" Publisher public library of science (plos)
2 results on '"Dirk Lebrecht"'

1. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Author

Nils Venhoff, Nora M Effelsberg, Ulrich Salzer, Klaus Warnatz, Hans Hartmut Peter, Dirk Lebrecht, Michael Schlesier, Reinhard E Voll, and Jens Thiel

Subjects
Medicine, Science
Abstract

OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. RESULTS: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p

Published
2012
Full Text
View/download PDF

2. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

Author

Dirk Lebrecht, Ulrich Salzer, Reinhard E. Voll, Klaus Warnatz, Nora M. Effelsberg, Nils Venhoff, J. Thiel, Michael Schlesier, and Hans-Hartmut Peter

Subjects
Male, B Cells, Lymphocyte, lcsh:Medicine, Adaptive Immunity, Hypogammaglobulinemia, Antibodies, Monoclonal, Murine-Derived, Interquartile range, lcsh:Science, B-Lymphocytes, Multidisciplinary, biology, Middle Aged, medicine.anatomical_structure, Monoclonal, Medicine, Rituximab, Female, Antibody, medicine.drug, Research Article, Vasculitis, Adult, Cyclophosphamide, Immune Cells, Immunoglobulins, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Immune Suppression, Autoimmune Diseases, Immune Deficiency, Rheumatology, medicine, Humans, Immunologic Factors, Lymphocyte Count, Wegener Granulomatosis, Antibody-Producing Cells, B cell, Aged, business.industry, lcsh:R, Immunity, Immune Defense, medicine.disease, Immunology, Humoral Immunity, biology.protein, Clinical Immunology, lcsh:Q, business
Abstract

Objective To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). Methods Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. Results CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results